Oral semaglutide trumps Jardiance, Januvia, Victoza in type II diabetes by Anna Smith | Sep 19, 2019 | News | 0 Type II diabetes costs the NHS £8.8 billion a year. Read More
Novo’s oral semaglutide hits targets in diabetics with renal impairment by Selina McKee | Aug 21, 2018 | News | 0 Novo Nordisk says trial data show an oral formulation of its GLP-1 analogue semaglutide provided superior HbA1c and weight reductions versus placebo in people with type II diabetes and renal impairment. Read More